Blood Test Reads DNA Methylation Patterns to Help Detect Deadly Esophageal Cancer

Esophageal squamous cell carcinoma, one of the most lethal malignancies worldwide, has long frustrated clinicians for a deceptively simple reason: by the time symptoms appear, the disease is usually advanced. Fewer than one in five patients survives five years after diagnosis, a statistic that has barely budged in decades despite advances in surgery, radiotherapy and chemotherapy. The bottleneck is early detection. Tumors growing within the esophageal lining can cause difficulty swallowing only once they have grown large enough to obstruct the lumen, and by then curative treatment is often no longer an option. Now a team of Chinese researchers reports a potential way forward that requires nothing more invasive than a routine blood draw, relying on chemical tags scattered across the genome that shift their patterns when cancer is present.

The study, published in BMC Medicine by Lanfei Bi, Wenli Li and colleagues working across Nanjing Medical University and several partner institutions, describes a DNA methylation panel measured in peripheral blood that can help distinguish patients with esophageal squamous cell carcinoma from healthy individuals. DNA methylation refers to the addition of methyl groups to cytosine bases, typically at cytosine-guanine dinucleotide sites known as CpG sites. These epigenetic marks regulate gene expression without altering the underlying DNA sequence, and they are among the earliest and most consistent molecular changes that occur during cancer development. Because tumor cells shed DNA into the bloodstream and because immune and blood cell populations themselves respond to malignancy, methylation patterns circulating in blood can serve as a molecular fingerprint of disease occurring elsewhere in the body.

The researchers focused on three genes: HYAL2, which encodes hyaluronan glucosidase 2, an enzyme involved in the breakdown of hyaluronic acid, a component of the extracellular matrix; S100P, a calcium-binding protein implicated in cell proliferation and metastatic behavior; and DYRK4, or dual-specificity tyrosine phosphorylation regulated kinase 4, a signaling kinase. All three have been linked to cancer biology in prior work, but the team’s goal was not simply to confirm their involvement. Instead, they wanted to quantify methylation at specific CpG sites within these genes precisely enough to build a diagnostic classifier, using mass spectrometry to measure methylation levels quantitatively rather than merely detecting the presence or absence of marks.

The study design rested on two independent case-control investigations with a combined total of 601 patients with esophageal squamous cell carcinoma and 802 healthy controls, a sample size that lends considerable statistical weight to the findings. In the first study, the team observed significant hypomethylation, meaning a loss of methyl marks, at 11 of the 16 CpG sites examined across the three genes. The effect was substantial: each 10 percent decrease in methylation was associated with odds ratios ranging from 1.35 to 1.94 for having the disease, with P-values below 0.004. In the second study, which enrolled patients with earlier-stage disease, hypomethylation was confirmed at 9 CpG sites within HYAL2 and S100P, with odds ratios between 1.27 and 1.69 per 10 percent methylation decrease and P-values below 0.001. The replication across two independent cohorts is a critical strength, since many candidate biomarkers fail precisely at this validation stage.

Perhaps the most intriguing biological observation was that methylation differences between cases and controls grew larger in advanced or more aggressive tumors. This dose-response-like relationship suggests that the methylation changes are not random epiphenomena but track with the progression of the malignancy itself. It also raises the possibility that a methylation panel of this kind could eventually carry prognostic information, hinting at tumor stage or aggressiveness before imaging or endoscopy provides that answer. The authors are careful, however, to frame the panel as an auxiliary diagnostic tool, one that would complement rather than replace endoscopic examination and biopsy, which remain the gold standard for confirming esophageal cancer.

To translate the methylation measurements into a practical classifier, the researchers used logistic regression, a statistical method that models the probability of disease as a function of multiple predictor variables while adjusting for covariates such as age and sex. They evaluated performance with receiver operating characteristic curves, summarizing discriminatory ability through the area under the curve, or AUC, a value of 1.0 indicating perfect separation between cases and controls and 0.5 indicating performance no better than chance. In the first study, the methylation panel achieved AUC values between 0.68 and 0.78. In the second study, with earlier-stage cases, the panel reached AUC values of 0.70 to 0.86, a notable result given that early-stage disease is typically the hardest to detect and the most clinically valuable target.

The decisive methodological innovation came when the team incorporated complete blood count parameters into the model. A standard complete blood count measures the proportions and absolute numbers of different circulating cell types, including neutrophils, lymphocytes, monocytes and platelets, and these values are routinely altered in cancer patients through inflammation and immune modulation. When the researchers adjusted the methylation panel of the second study for these hematological parameters, the discriminatory ability improved markedly, yielding AUC values between 0.80 and 0.91 for detecting esophageal squamous cell carcinoma. The logic is elegant: methylation marks capture tumor-derived and tumor-responsive molecular signals, while blood count parameters capture the systemic physiological response to malignancy, and combining the two layers of information produces a classifier stronger than either alone.

The technical pipeline behind the measurements deserves attention as well. Quantitative methylation determination by mass spectrometry, following enzymatic processing steps that included shrimp alkaline phosphatase treatment, offers precision that older qualitative methylation assays lack. The researchers also controlled for potential confounders such as single nucleotide polymorphisms, which can interfere with methylation quantification at nearby CpG sites. Ethics approval was obtained from Nanjing Medical University and the Cancer Hospital of the Chinese Academy of Medical Sciences, and written informed consent was collected from all participants, with the authors declaring no competing interests.

The clinical implications are considerable, particularly for regions where esophageal squamous cell carcinoma is endemic. The disease shows striking geographic clustering, with high-incidence areas in parts of China, Iran and East Africa, where rates can be many times higher than the global average. In such settings, population-wide endoscopic screening is expensive, resource-intensive and uncomfortable for patients, which limits uptake. A blood-based test that could triage individuals for endoscopic follow-up would concentrate invasive procedures on those most likely to benefit. Because the panel relies on quantitative methylation signatures and standard blood count parameters, both of which can be measured in a conventional clinical laboratory, the authors argue that it represents a feasible and efficient strategy for in vitro auxiliary diagnosis.

Cautious interpretation remains essential. Case-control studies demonstrate association and classification performance but do not establish how the panel would perform in a true screening population, where the prevalence of disease is far lower than in a case-control design and false positives carry real costs. Prospective validation in independent cohorts, ideally including patients with premalignant lesions and other esophageal or inflammatory conditions, will be needed to define the panel’s specificity and its place in clinical guidelines. Nevertheless, the study adds to a rapidly growing body of work showing that epigenetic signatures in blood can reveal cancers that are otherwise invisible until late stages. If the findings hold up in larger, population-based trials, a simple blood test reading the methylation patterns of HYAL2, S100P and DYRK4, combined with routine blood count data, could become a powerful ally in catching one of the world’s deadliest cancers while it is still curable.

Subject of Research: A peripheral blood DNA methylation panel for auxiliary diagnosis of esophageal squamous cell carcinoma

Article Title: Peripheral blood-based DNA methylation panel for auxiliary diagnosis of esophageal squamous cell carcinoma

Article References: Bi, L., Li, W., Gu, W., Jin, D., Zhao, Z., Zhao, L., Wu, J., Zhang, J., Song, Y., Jiang, Y., & Yang, R. (2026). Peripheral blood-based DNA methylation panel for auxiliary diagnosis of esophageal squamous cell carcinoma. BMC Medicine. https://doi.org/10.1186/s12916-026-05209-9

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05209-9

Keywords: DNA methylation, esophageal squamous cell carcinoma, epigenetics, biomarkers, HYAL2, S100P, DYRK4, blood test, cancer diagnosis, complete blood count, mass spectrometry, early detection